Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03425331
Recruitment Status : Suspended (Slow accrual, competing studies, and lack of efficacy)
First Posted : February 7, 2018
Last Update Posted : November 23, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Mark Awad, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Suspended
Actual Primary Completion Date : August 28, 2021
Estimated Study Completion Date : August 28, 2025